AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05752409
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2mg•kg-1propofol for general anesthesia induction.
Trial: NCT05775705
Drug: L-DEP and PD-1 antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (doxorubicin hydrochloride liposome injection) 35 mg/m2 day 1; etoposide 75 mg/m2 day1; methylprednisolone 1.5mg/kg days 1 to 3, 0.25mg/kg day 4 to 14; PEG-aspargase 6000iu/m2 day2, day4; PD-1 antibody injection 200mg day 5.
Trial: NCT05951686
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In inhalation group, desflurane will be used for general anesthesia maintenance under the screening with Patient State Index (PSI) between a score of 25-50. Remifentanil infusion is used with desflurane with a dose of 0.05-2 mcg/ kg/ min according to PSI . Fresh gas flow is used 2 L/ min with a mixture of 50%- 50% oxygen and medical air in both groups.
Trial: NCT05951686
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion will be used for general anesthesia maintenance with a dose of under the screening of Patient State Index (PSI) between a score of 25-50 in group tiva.
Trial: NCT04847921
Drug: Dalbavancin
RxNorm normalized name: Dalbavancin
DrugBank: Dalbavancin (DB06219)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: long-acting lipoglycopeptide antibacterial agent
Trial: NCT04731116
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Cannabidiol 150 mg twice daily during 14 days
Trial: NCT06193720
Drug: Arnica montana
RxNorm normalized name: Arnica montana
DrugBank: Arnica montana (DB14297)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assess the effect of arnica montana on pain, swelling ans trismus after impacted third molar surgery
Trial: NCT05551897
Drug: Camizestrant
RxNorm normalized name: Camizestrant
DrugBank: Camizestrant (DB19218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered a single oral dose of Camizestrant on Day 1 of treatment period 1 and treatment period 3.
Trial: NCT05551897
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be administered Itraconazole twice a day on Day 1 and once daily on Day 2 and Day 3 of treatment period 2, and once daily on Day 1, 2 and 3 of treatment period 3.
Trial: NCT05910398
Drug: pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an irreversible anti-HER2 tyrosine kinase inhibitor
Trial: NCT05499936
Drug: 68Ga-FAPI
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68Ga-FAPI were injected into the patients before the PET/CT scans
Trial: NCT06430060
Drug: MFP Fluoride toothpaste
RxNorm normalized name: sodium fluoride Toothpaste [Fluoridex]
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: toothpaste
Trial: NCT04740970
Drug: JNJ-64304500
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-64304500 injection will be administered subcutaneously.
Trial: NCT04773301
Drug: Levobupivacaine
RxNorm normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local anaesthetic drug belonging to the amino amide group. It is the S-enantiomer of bupivacaine
Trial: NCT06403501
Drug: Clascoterone
RxNorm normalized name: Clascoterone
DrugBank: Clascoterone (DB12499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clascoterone Cream 1% (Winlevi) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Trial: NCT05161936
Drug: Lumasiran
RxNorm normalized name: lumasiran
DrugBank: Lumasiran (DB15935)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lumasiran will be administered by SC injection.
Trial: NCT05371197
Drug: Neoadjuvant therapy with PD-L1 inhibitor
RxNorm normalized name: PD-L1/4-1BB bispecific antibody
DrugBank: ATG-101 (DB17162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy with PD-L1 inhibitor (Envafolimab), 300mg, Q3W for 4 cycles
Trial: NCT04773301
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local anaesthetic drug belonging to the amino amide group. The name ropivacaine refers to both the racemate and the marketed S-enantiomer.
Trial: NCT05721027
Drug: Dexamethasone Oral
RxNorm normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 16 mg PO during ED visit and next day
Trial: NCT05768464
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240mg intravenously every 3 weeks
Trial: NCT05768464
Drug: Axitinib
RxNorm normalized name: Axitinib
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg orraly twice daily
Trial: NCT04837170
Drug: Conventional therapy + S (+)-Ketamine
RxNorm normalized name: (S)-(-)-ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who undergo general anesthesia using S(+)-ketamine hydrochloride for anesthesia induction,maintenance or postoperative analgesia.
Trial: NCT05611034
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin infusion in single lung via IVLP technique
Trial: NCT05167448
Drug: ES104
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ES104 is administered via Intravenous infusion, at dose of 10 mg/kg, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
Trial: NCT05167448
Drug: ES104
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ES104 is administered via Intravenous infusion, at dose of 12.5 mg/kg, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
Trial: NCT05167448
Drug: ES104
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ES104 is administered via Intravenous infusion, at dose of RP2D, once every 14 days, every 28 days as a treatment cycle for a maximum treatment duration per patient of 2 years.
Trial: NCT05797090
Drug: Crystalloid Cardioplegic solution
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To compare between conventional crystalloid cardioplegia with modified del Nido cardioplegia in mitral valve regurge replacement surgery.
Trial: NCT00002308
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04801693
Drug: BI 1819479
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1819479
Trial: NCT04817982
Drug: Perineural dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 4mg will be added perineurally to an ulnar nerve block with bupivacaine.
Trial: NCT04817982
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 40 mg will be added perineurally to an ulnar nerve block with bupivacaine.
Trial: NCT04817982
Drug: Systemic dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone will be added perineurally to an ulnar nerve block with bupivacaine, some will be reabsorbed and distributed systemically. Thereby, the investigators control for the systemic effects of adding perineural dexamethasone to an ulnar nerve block.
Trial: NCT05442632
Drug: Hetrombopag
RxNorm normalized name: Hetrombopag
DrugBank: Hetrombopag (DB16184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients received Hetrombopag 5mg orally d1-14 days, surgery will be conducted at d6-14 day
Trial: NCT05876312
Drug: ADX-038
RxNorm normalized name: ADX 102
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: siRNA duplex oligonucleotide
Trial: NCT05265676
Drug: Enoxaparin Sodium (Venus Remedies Limited)
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The test drug is enoxaparin sodium pre-filled syringe 40 mg/0.4mL of Venus Remedies Limited, India
Trial: NCT05265676
Drug: Enoxaparin Sodium (Sanofi)
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The reference drug is enoxaparin sodium pre-filled syringe 40 mg/0.4mL of Sanofi, Germany
Trial: NCT04093076
Drug: INO-4500
RxNorm normalized name: INO
DrugBank: Inosine (DB04335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: INO-4500 will be administered ID on Day 0 and Week 4.
Trial: NCT05593458
Drug: Oxaliplatin by arterial infusion plus S-1
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 cycles oxaliplatin by arterial infusion plus S-1 every 21 days as neoadjuvant chemotherapy.
Trial: NCT05593458
Drug: Sintilimab neoadjuvant
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles of neoadjuvant immunotherapy every 21 days.
Trial: NCT05593458
Drug: Sintilimab adjuvant
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles of adjuvant immunotherapy every 21 days.
Trial: NCT06060886
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral dose range 5-30 mg/day (100 mg- 600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence.
Trial: NCT06060886
Drug: Paliperidone
RxNorm normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral dose range 3-12 mg/day (150mg-600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence
Trial: NCT05363800
Drug: HRS-3738
RxNorm normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS-3738 will be administrated per dose level in which the patients are assigned.
Trial: NCT04782089
Drug: Camrelizumab Anti-PD-1 antibody Fluzoparib PARP inhibitors
RxNorm normalized name: anti-inhibitor coagulant complex 1 UNT
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab+Fluzoparib：Q3W, Administration until disease progression or intolerable
Trial: NCT05020912
Drug: ALA
RxNorm normalized name: ALA
DrugBank: alpha-Linolenic acid (DB00132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At first visit, ALA applied to one BCC lesion
Trial: NCT05207358
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 doses of Rituximab 1 g and Methylprednisolone 500 mg on days 1 and 15.
Trial: NCT05207358
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive Mycophenolate Mofetil, initially 500 mg twice daily, titrated to a maximum of 1.5 g twice daily, depending on leukocyte count and digestive tolerance, which will be maintained 24 months.
Trial: NCT05124678
Drug: Isoniazid Tablets
RxNorm normalized name: Isoniazid Tablets
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High dose of isoniazid
Trial: NCT05332795
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: gouty patients, will receive metformin tablets (1000 mg) once daily for about 3 months.
Trial: NCT06337409
Drug: Generic empagliflozin 25 mg film-coated tablets
RxNorm normalized name: empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin 25 mg film-coated tablets
Trial: NCT06215833
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All children will undergo anesthesia via Propofol bolus injection in induction then Propofol infusion in maintenance of anesthesia and will be given after total recovery, Cetal suppositories as postoperative analgesia
Trial: NCT06215833
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All children will undergo anesthesia via Sevoflurane will be given during induction then through maintenance of anesthesia and will be given after total recovery, Cetal suppositories as post operative analgesia
Trial: NCT06540469
Drug: anti-Thyroid Drugs
RxNorm normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized methimazole (MMI)
Trial: NCT05702151
Drug: Morphine injection
RxNorm normalized name: morphine Injection
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous morphine infusion 50mcg/kg/h with Patient Controlled Analgesia extra bolus on demand (1mg bolus with 20 minutes lockout time), and paracetamol 1g every 8 hours.
Trial: NCT06217146
Drug: Medical Cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MediCane's medical cannabis oil
Trial: NCT05408936
Drug: SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive an SGLT2 inhibitor as part of theirn routine care.
Trial: NCT04915482
Drug: Combined use of TPO-RAs with low-dose anti-CD20 antibody
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Experimental: Combined use of TPO-RAs with low-dose anti-CD20 antibody The starting dose of eltrombopag is 50-75mg once daily. The starting dose of hetrombopag is 5.0-7.5mg once daily. The starting dose of avatrombopag is 20-40mg once daily. Prior to or within 2 weeks after initiation of TPO-RAs therapy, a single dose of Rituximab at 375mg/m2 or divided doses of Rituximab at 100mg once a week for 2-4 weeks, or a single dose of ortuzumab at 1000mg can be administered.. The dosage will be adjusted according to the results of laboratory examinations and patient tolerance.
Trial: NCT02973620
Drug: Levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levosimendan infusion started at 0.1 mcg/kg/min for 6-12 hours, increased to 0.2 mcg/kg/min for 24-36 hours
Trial: NCT04828525
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: adjuvant dexamethasone treatment
Trial: NCT05320588
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Programmed death receptor-1 (PD 1)-blocking antibody
Trial: NCT05436288
Drug: KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KIO-201 is a stand-alone drug therapy that acts as a barrier that minimizes mechanical lid friction and mechanically protects the ocular surface thereby reducing repeat injury and providing an environment that enables the body to repair the ocular surface whether the corneal epithelial defects are large or small.
Trial: NCT05789342
Drug: GP681
RxNorm normalized name: Guanfacine
DrugBank: Guanfacine (DB01018)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GP681, tablet, oral
Trial: NCT05789342
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin, tablet, oral
Trial: NCT05789342
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole, capsule, oral
Trial: NCT05789342
Drug: Oseltamivir
RxNorm normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oseltamivir, capsule, oral
Trial: NCT00000975
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05099276
Drug: Tranexamic Acid Pill
RxNorm normalized name: tranexamic acid Pill
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1950 mg tranexamic acid (three capsules) given in post-anesthesia room and three capsules for postop day one and three capsules for postop day two
Trial: NCT04915482
Drug: The best available therapy
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The best available therapy except for combined use of TPO-RAs with low-dose anti-CD20 antibody includes but not limited to glucocorticoids, intravenous immunoglobulin, recombinant human thrombopoietin, TPO receptor agonists monotherapy, rituximab monotherapy, immunosuppressants, etc., and the researchers will adjust the treatment plan at any time according to the patient's condition.
Trial: NCT00232921
Drug: caudal volume 3
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06367114
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine is used for lymphodepletion.
Trial: NCT00000839
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06488001
Drug: pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40mg given the night before surgery, 2 hours prior to surgery, and the evening after surgery.
Trial: NCT05296278
Drug: IBI-323 combined with bevacizumab plus Platinum
RxNorm normalized name: platinum
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IBI-323 (30 mg/kg) ccombined with bevacizumab (15 mg/kg) plus platinum based chemotherapy ivgtt, every 21 days until disease progression
Trial: NCT06413771
Drug: Letrozole 2.5mg
RxNorm normalized name: LETROZOLE 2.5MG TAB
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole pretreatment during ovarian stimulation with gonadotropins, in intrauterine insemination cycles.
Trial: NCT06413771
Drug: Gonadotropin
RxNorm normalized name: Gonadotropin
DrugBank: Choriogonadotropin alfa (DB00097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ovarian stimulation with gonadotropins, in intrauterine insemination cycles.
Trial: NCT05314725
Drug: SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 days of SGLT2 inhibitor after surgery
Trial: NCT04329806
Drug: Moxonidine 0.2 MG
RxNorm normalized name: moxonidine 0.2 MG
DrugBank: Moxonidine (DB09242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine 0.2 MG twice daily
Trial: NCT04329806
Drug: Amlodipine 5 MG
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 MG twice daily
Trial: NCT05570422
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Weekly concomitant cisplatin (40 mg/m2) during EBRT~* Neo-adjuvant chemotherapy or other forms of antineoplastic treatment apart from weekly concomitant cisplatin (40 mg/m2) are not allowed.~* Adjuvant chemotherapy (after completion of EBRT+BT) is not allowed.
Trial: NCT04772547
Drug: Vigabatrin Only Product
RxNorm normalized name: Vigabatrin only product
DrugBank: Vigabatrin (DB01080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: enteral medication administration, serial blood draws, and outcome assessment
Trial: NCT06341283
Drug: Abemaciclib and Letrozole/Anastrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Take the treatment with Abemaciclib and Letrozole/Anastrozole at the same time.
Trial: NCT06341283
Drug: Letrozole or Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Take the treatment with Letrozole or Anastrozole.
Trial: NCT06341283
Drug: Abemaciclib and Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Take the treatment with Abemaciclib and Fulvestrant at the same time.
Trial: NCT06341283
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Take the treatment with Fulvestrant only.
Trial: NCT05509374
Drug: Carfilzomib 56 MG [Kyprolis]
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carfilzomib 56 mg/m2 (Day1, 8, 15) (Cycle1 Day1, 20 mg/m2)
Trial: NCT05509374
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide 4 mg per os (Day1-21)
Trial: NCT05509374
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 40 mg (D1, 8, 15, 22) (20 mg for patients ≥ 75 years old)
Trial: NCT04935515
Drug: Oral Antibiotic, Antihistamine, Anti-inflammatory, Multivitamins
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Azithromycin , Cetirizine, Paracetamol, Zinc, Vitamin C, Vitamin D